Compare NRG Energy Inc (NRG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs TransMedics Group Inc — how do they compare? NRG Energy Inc trades at $107.97 (market cap $22.35B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: NRG Energy Inc is far larger — about 8.2× TransMedics Group Inc's market cap, and NRG Energy Inc pays a 1.79% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 63 Days and TransMedics Group Inc for 24 Days on average.
| NRG | TMDX | |
|---|---|---|
Market Cap | $22.35B | $2.74B |
Volume | 5,011,942 | 949,331 |
Sector | Utilities | Health |
52-Week High | $184.03 | $150.42 |
52-Week Low | $95.23 | $61.99 |
Typical Hold Time | 63 Days | 24 Days |
Enterprise Value | $46.30B | $3.13B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $106.32, down 2.11% today, with a bullish technical signal and strong analyst support. The stock shows mixed earnings performance with recent misses but maintains solid fundamentals including $30.71B revenue and 2.56% net margin. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant, positioning for growth in energy infrastructure.
Outlook remains positive with 70% analyst buy ratings and $202.90 consensus price target representing 91% upside. Key risks include execution of major capital projects, debt levels at 56.42% of assets, and energy market volatility. The dividend yield of approximately 1.6% provides income support while growth initiatives drive long-term potential.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
